Elron Ventures Ltd · TASE:ELRN
Elron Ventures — Elron Electronic Industries — Investor Presentation (March 2011)
33 slides from Elron Ventures's investor presentation, Mar 28, 2011
Slide 1: Company Presentation March 2011
COMPANY PRESENTATION MARCH 2011
Slide 2: Forward-Looking Information
Forward-Looking Information This presentation is for information purposes only. By this presentation, Elron does not intend to solicit offers to purchase its securities and the presentation does not constitute an invitation to receive such offers. Elron may make improvements and/or changes in the fe
Slide 3: Elron 09-10 Overview
Slide 4: Elron 09-10: Management and organizational measures
ELRON 09-10 In the first half of 2009, Elron began implementing a series of management and organizational measures FOCUSING ACTIVITIES IDENTIFYING OPPORTUNITIES REDUCING COSTS
Slide 5: Focusing investments in core companies
ELRON 09-10 FOCUSING INVESTMENTS IN CORE COMPANIES Reducing investments in companies with limited potential
Slide 6: Reduction in number of group companies
ELRON 09-10 a / a | From 2008 to 2010 the number of group companies was reduced by
Slide 7: Investments and exits 2006-2010
ELRON 09-10 68.5 millon $ 33.5 36.7 ames mana 21 2 — {2010 : M2006 | 2010 Investments m Exits mi * including earn-out and escrow amounts from the sale of Medingo
Slide 8: Realization
| REALIZATION J a
Slide 9: Investments Realization: Sale of Medingo
INVESTMENTS REALIZATION i May 2010 Sale of Medingo to F. Hoffman-LayRoche in Switzerland for ~$'200,000,000 “The proceeds from the sale of Medingo include earn-out and escrow amounts.
Slide 10: Investments Realization: Sale of NetVision
INVESTMENTS REALIZATION i October 2009 Sale of Elron's holding in NetVision toIDB ~ group companies for
Slide 11: Investments Realization: Sale of Teledata
INVESTMENTS REALIZATION .Y June 2010 Sale of Teledata by way of merger to Sy Enablence in Canada for ~$50,000, 000 Op isscze
Slide 12: New management team and cost reduction
ELRON 09-10 New management team appointed Manpower reduced by half Entered into Services Agreement with DIC (compared to 2008)
Slide 13: Income (Loss) Development 2008-2010
ELRON 09-10 Income (Loss)* Development 2008-2010 Medingo and Teledata Exits 3DV Exit eo Ed — 45 3, 12.2 11.5 ic =e in 24.0 milion $ Qos = Q2/os. 5/08 »Company/s shareholders Qa/os §—Qi/ovQ2/0p,- 3/09 Qa/op, Qi/10. Qa/loQ8/10Qa/10.
Slide 14: Net income for 2010
ELRON 09-10 Net income * for 2010 amounted to ~$61 wi $ million * attributable to Cor
Slide 15: Spotlight
a J SPOTLIGHT 201 m. es ® ‘I = , es b a
Slide 16: Spotlight 2011
SPOTLIGHT 2011
Slide 17: Spotlight 2011: Pocared diagnostics system
SPOTLIGHT 2011 High throughput in-vitro diagnostics (IVD) system. Rapid, automated microbiological testing of pathogens in body fluids based on optical technology. Tec! nt Real-time diagnosis, whereas current methods take 24-72 hrs. Automated, whereas current methods require highly-trained technicia
Slide 18: Pocared next milestones
SPOTLIGHT 2011 Pocared expects to commence a broad diagnostic clinical trial during the second half of 2011. Also, Pocared intends to act toward obtaining the CE Mark for the product under its development during 2011.
Slide 19: Spotlight 2011: BrainsGate
SPOTLIGHT 2011 Broad platform technology for treatment of central nervous system diseases. Stimulates the SPG (a nerve center located behind the nasal cavity) to increase blood flow to the brain using a miniature implantable electrode. Additional investors include Johnson & Johnson. Enables treatmen
Slide 20: BrainsGate next milestone
SPOTLIGHT 2011 @)| BrainsGate Delivering new hope to the mind NEXT MILESTONE BrainsGate is working towards improving its clinical trial protocol, and expects to commence an IDE clinical trial based on a new protocol during 2011.
Slide 21: Spotlight 2011: NuLens
SPOTLIGHT 2011 First real accommodating intraocular lens ("IOL") for implantation in Cataract and Impaired Vision patients. Additional investors include Warburg Pincus. Expected to provide over 6 diopters of accommodative paver compared to 1-2 diopters today. lesigned to mimic the natural function o
Slide 22: NuLens next milestone
SPOTLIGHT 2011 ONuLeny.:. NEXT MILESTONE NuLens expects to commence an IDE clinical trial during the first half of 2012.
Slide 23: Holdings in companies at various stages of development
SPOTLIGHT 2011 Holdings in Companies at Various Stages Of Development Initial R&D / IDE/FDA CE-/FDA-clearance Initial Revenues Accelerated Significant Clinical Trials Trials 1 Pre-commercialization Revenues Revenues
Slide 24: Looking Forward
LOOKING | FORWARD
Slide 25: Looking Forward: IDB access, RDC and Rafael
LOOKING FORWARD f Access to IDB Holding Deal Flow Company Provensuccessin One of Israel's most (not (@) Focusing on building break- influential business Flexibility for long- creating leading RDC: Strategic part- through companies enterprises term support and global companies nership between commitm
Slide 26: Looking Forward: strategy and focus on medical devices
“I LOOKING FORWARD * » » é The Company is continuing to implement a strategy of identify- ing and building leading companies based on Israeli technology. Seeking investments with a focus on medical devices, in which Elron has experience, connections & proven capabilities. Continuing to invest throug
Slide 27: Implementing Elron's strategy
LOOKING FORWARD Implementing Elron's Strategy [zoos 2007S 2009S 2010S November 2005 November 2007 July 2009 “cumulative investment
Slide 28: Identifying opportunities: investment in Kyma
bs LOOKING FORWARD ae eee Identifying Opportunities: Investment in monitoring of chronic heart failure (CHF) patients. The device comprises of a miniature patch attached to the patient's torso. Technological Advantage Data is transferred wirelessly, enabling remote monitoring, early treatment, and a
Slide 29: Finance
> ws 4 «>? |FINANCE
Slide 30: Finance: 2010 results
FINANCE 2010 Results 2008 2009 2010 Net Income for 2010 Income (loss) attributable to (71.8) (143) 60.7 ($ million) shareholders Main contributors to Equity in losses of group companies 56.1 27.4 23.7 income (loss) ($ millions)* “net of non-controlling interest and of tax — Excess cost amortization
Slide 31: Statement of financial position
FINANCE Cash and cash equivalents 565 647 STAT E M E N T Current assets and assets held fr sale (excluding ash) 30.3, 92 Long-term investments. 129.6 127.8 Oo F Property plant & equipment, net 2a 30 Intangible assets 36 75 FINANCIAL cmiccicrnss POSITION a Current liabilities Short-term loans 09 109
Slide 32: Net cash development
Net cash development bt ayy 40.7 eet c 30.0 23.8 mrlion $ milion § 13.2 0 rrilion 12.5 LI millon’ 20.8 . ‘millon 31.8 32.0 . mnilions ‘millions 56,7 millions § 39.0 millon Qi/os Q2/os. | Q3/o8. «| a/os. «= Qt/0- 2/09 3/09 = Qu/o9 Q/1I0 alo. 8/10» Qa/t0 ‘Quarter/Year
Slide 33: Thank You
THANK YOU ELRON ELECTRONIC INDUSTRIES LTD WWW.ELRON.COM +972-3-6075555 ELRON@ELRON.COM
Elron Electronic Industries — Investor Presentation (March 2011) on 6ix